FROM THE FOUNDATION

Redefining the Safety Net

Should California establish a Basic Health Program for certain low-income residents? CHCF's Marian Mulkey captures a recent policy conversation in a Health Affairs blog.

Accountable Care in Action

A new post on the Health Affairs blog details how CalPERS kept costs down in Sacramento through a "virtual" ACO with insurers and providers.

Career Opportunity: Senior Program Officer

This position will play a major role in furthering the goals and objectives of the foundation's Better Chronic Disease Care program.

Chronic Disease Care

Wednesday, February 01, 2012

FDA OKs Genentech Drug To Treat Advanced Skin Cancer

On Monday, FDA approved the first drug to treat an advanced form of basal cell carcinoma, the most common type of skin cancer. The drug -- known generically as vismodegib -- will be marketed as Erivedge by California-based Genentech. The company estimates that a 10-month treatment course would cost about $75,000.



Readers are invited to send feedback to: chl@chcf.org